Top Industry Leaders in the Pulmonary Atresia Diagnostics Treatment Market
Latest Pulmonary Atresia Diagnostics and Treatment Companies Updates:
Philips: Introduced the Azurion MaxPulse interventional X-ray system featuring enhanced functionalities for complex congenital heart procedures, including those for pulmonary atresia.
Abbott: Expanded the label of its Amplatzer™ Septal Occluder for transcatheter closure of atrial septal defects (ASDs), offering a minimally invasive option for patients with pulmonary atresia who also have an ASD.
Sapiens Transcatheter Solutions: Developed the Harmony Transcatheter Pulmonary Valve system, designed for minimally invasive replacement of malfunctioning pulmonary valves in patients with pulmonary atresia, potentially reducing procedural risks and complications.
Medtronic: Acquired Intersect Medical, gaining access to Intersect's transcatheter aortic valve replacement (TAVR) technology, which could potentially be adapted for future applications in pulmonary valve replacement for patients with pulmonary atresia.
Boston Scientific: Partnered with Children's Hospital Los Angeles to develop and evaluate novel interventions for treating complex congenital heart defects, including pulmonary atresia.
List of Pulmonary Atresia Diagnostics and Treatment Key companies in the market:
- Kyowa Pharma Chemical Co. Ltd
- AZAD partners
- Abbott Laboratories
- Dickinson and Company
- Becton
- C. R. Bard, Inc.
- B. Braun Melsungen AG
- Medtronic plc.
- Teleflex Incorporated
- JOHNSON & JOHNSON
- Cook Group Incorporated